

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Baijin Life Science Holdings Limited

佰金生命科學控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1466)

DATE OF BOARD MEETING

Reference is made to the announcements of Baijin Life Science Holdings Limited (the “**Company**”) (the “**Announcements**”) dated 25 June 2025 and 30 June 2025 in relation to, among others, the delay in publication of the 2025 Annual Results. Unless otherwise specified, capitalised terms in this announcement shall have the same meanings as those set out in the Announcements.

The board of directors (the “**Board**”) of the Company hereby announces that a meeting of the Board will be held on Friday, 25 July 2025 for the purpose of, among other matters, approving the announcement of the final results of the Company and its subsidiaries for the year ended 31 March 2025 and considering the recommendation on the payment of a final dividend, if any.

CONTINUED SUSPENSION OF TRADING

Trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on Wednesday, 2 July 2025, and will remain suspended pending the publication of the 2025 Annual Results.

Shareholders and potential investors are advised to exercise caution in dealing in the securities of the Company.

By order of the Board
BAIJIN LIFE SCIENCE HOLDINGS LIMITED
Cheung Sze Ming
Executive Director

Hong Kong, 15 July 2025

As at the date of this announcement, the Board comprises Mr. Cheung Sze Ming, Mr. Dong Peng and Dr. Su Yaoyao as executive Directors; Mr. Zhu Yongjun, Mr. Cheng Chi Kin and Ms. Xie Chunchen as non-executive Directors; Mr. Wong Siu Keung Joe, Mr. Chang Chunyu and Mr. Lee Ka Leung Daniel as independent non-executive Directors.